Vivek Thappa, MD
Sleep Medicine · Rockford, ILNPI 1295743383
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,671 of the $6,778 with a category attached, or 83.7%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 247 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Intuitive Surgical$989
- GSK$690
- Jazz Pharmaceuticals Inc.$652
- Sanofi$295
- plus $2K from 24 others
What the payments were for
- Travel & lodging$83512%
- Food & beverage$5,67184%
- Education$2734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,504 |
| Boehringer Ingelheim | 50 | $1,126 |
| Intuitive Surgical | 5 | $989 |
| GSK | 48 | $690 |
| Jazz Pharmaceuticals Inc. | 12 | $652 |
| Sanofi | 8 | $295 |
| Regeneron Healthcare Solutions, Inc. | 8 | $169 |
| Johnson & Johnson | 4 | $162 |
| Genentech USA, Inc. | 18 | $158 |
| Philips North America LLC | 7 | $120 |
| Inspire Medical Systems, Inc. | 2 | $115 |
| Actelion Pharmaceuticals US, Inc. | 5 | $101 |
| Sunovion Pharmaceuticals Inc. | 9 | $85 |
| Amgen | 4 | $85 |
| Mylan Specialty L.p. | 5 | $82 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| AbbVie | 3 | $53 |
| Verona Pharma, Inc. | 2 | $50 |
| Novartis | 3 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $43 |
| United Therapeutics Corporation | 2 | $31 |
| Grifols USA, LLC | 1 | $24 |
| Vapotherm Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $18 |
| Merck | 1 | $18 |
| Ambu Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,778 in reported general payments places this provider in the 80th percentile of 79 sleep medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $514,968 |
| Breo ElliptaFluticasone/Vilanterol | 247 | $125,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $65,829 |
| NucalaMepolizumab | 12 | $43,637 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $21,394 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $8,323 |
| Atrovent HfaIpratropium Bromide | 17 | $8,242 |
| DuleraMometasone/Formoterol | 23 | $7,953 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $7,824 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $6,040 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,845 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,557 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 167 | $4,208 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat | $1,126 | $520,23750 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $690 | $266,779402 claims |
| AstraZenecaSymbicort | $1,504 | $8,32318 claims |
| MerckDulera | $18 | $7,95323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 sleep medicine providers in Illinois.
Other sleep medicine in Rockford
- Muhammad NajjarNorthbrook$479K
- Phyllis ZeeChicago$214K
- Thomas FreedomGlenview$124K
- Syed SayeeduddinBrookfield$65K
- Hrayr AttarianChicago$43K
- Reena Dhanda-PatilChicago$41K
- Amy GuralnickChicago$19K
- Ahmer AliLake Barrington$15K
- Nawaid ShakirSchaumburg$15K
- Anna IvanenkoElk Grove Village$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.